Oncorus, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONCR research report →
Companywww.oncorus.com
Oncorus, Inc. , a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
- CEO
- Craig R. Jalbert CIRA
- IPO
- 2020
- Employees
- 64
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -0.04
- P/S
- 0.00
- P/B
- 0.05
- EV/EBITDA
- -0.59
- Div Yield
- 110.58%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -82.19%
- ROIC
- -59.36%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-78,307,000 · -21.04%
- EPS
- $-3.02 · -17.97%
- Op Income
- $-76,537,000
- FCF YoY
- -37.47%
Performance & Tape
- 52W High
- $0.47
- 52W Low
- $0.01
- 50D MA
- $0.03
- 200D MA
- $0.10
- Beta
- 1.95
- Avg Volume
- 108.67K
Get TickerSpark's AI analysis on ONCR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 6, 23 | Shea Brian J. | other | 0 |
| Jun 6, 23 | Shea Brian J. | other | 3,744 |
| Jun 6, 23 | Shea Brian J. | other | 14,700 |
| Jun 6, 23 | Shea Brian J. | other | 15,000 |
| Jun 6, 23 | Shea Brian J. | other | 19,100 |
| May 9, 23 | Nolte Alexander | other | 0 |
| Dec 28, 22 | Flynn James E | sell | 24,757 |
| Dec 29, 22 | Flynn James E | sell | 63,107 |
| Dec 29, 22 | Flynn James E | sell | 63,108 |
| Dec 30, 22 | Flynn James E | sell | 61,826 |
Our ONCR Coverage
We haven't published any research on ONCR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ONCR Report →